2005 SESSION

055515820 **SENATE BILL NO. 1178** 1 2 AMENDMENT IN THE NATURE OF A SUBSTITUTE 3 (Proposed by the Senate Committee for Courts of Justice 4 on February 2, 2005) 5 6 (Patron Prior to Substitute—Senator Stolle) A BILL to amend and reenact §§ 18.2-247, 54.1-3457 and 54.1-3458 of the Code of Virginia, relating to 7 counterfeiting prescription drugs; penalty. 8 Be it enacted by the General Assembly of Virginia: 9 1. That §§ 18.2-247, 54.1-3457 and 54.1-3458 of the Code of Virginia are amended and reenacted 10 as follows: § 18.2-247. Use of terms "controlled substances," "marijuana," "Schedules I, II, III, IV, V and VI," 11 and "imitation controlled substance" in Title 18.2. 12 A. Wherever the terms "controlled substances" and "Schedules I, II, III, IV, V and VI" are used in 13 14 Title 18.2, such terms refer to those terms as they are used or defined in the Drug Control Act 15 (§ 54.1-3400 et seq.). B. The term "imitation controlled substance" when used in this article means (i) a counterfeit 16 17 controlled substance or (ii) a pill, capsule, tablet, or substance in any form whatsoever which is not a controlled substance subject to abuse, and: 18 1. Which by overall dosage unit appearance, including color, shape, size, marking and packaging or 19 20 by representations made, would cause the likelihood that such a pill, capsule, tablet, or substance in any 21 other form whatsoever will be mistaken for a controlled substance unless such substance was introduced into commerce prior to the initial introduction into commerce of the controlled substance which it is 22 23 alleged to imitate: or 24 $\overline{2}$. Which by express or implied representations purports to act like a controlled substance as a 25 stimulant or depressant of the central nervous system and which is not commonly used or recognized for use in that particular formulation for any purpose other than for such stimulant or depressant effect, 26 unless marketed, promoted, or sold as permitted by the United States Food and Drug Administration. 27 28 C. In determining whether a pill, capsule, tablet, or substance in any other form whatsoever, is an 29 "imitation controlled substance," there shall be considered, in addition to all other relevant factors, 30 comparisons with accepted methods of marketing for legitimate nonprescription drugs for medicinal 31 purposes rather than for drug abuse or any similar nonmedicinal use, including consideration of the 32 packaging of the drug and its appearance in overall finished dosage form, promotional materials or 33 representations, oral or written, concerning the drug, and the methods of distribution of the drug and 34 where and how it is sold to the public. 35 D. The term "marijuana" when used in this article means any part of a plant of the genus Cannabis, 36 whether growing or not, its seeds or resin; and every compound, manufacture, salt, derivative, mixture, 37 or preparation of such plant, its seeds, or its resin. Marijuana shall not include any oily extract 38 containing one or more cannabinoids unless such extract contains less than 12 percent of 39 tetrahydrocannabinol by weight, or the mature stalks of such plant, fiber produced from such stalk, oil 40 or cake made from the seed of such plant, unless such stalks, fiber, oil or cake is combined with other 41 parts of plants of the genus Cannabis. 42 E. The term "counterfeit controlled substance" means a controlled substance that, without 43 authorization, bears, is packaged in a container or wrapper that bears, or is otherwise labeled to bear, the trademark, trade name, or other identifying mark, imprint or device or any likeness thereof, of a drug 44 manufacturer, processor, packer, or distributor other than the manufacturer, processor, packer, or 45 distributor who did in fact so manufacture, process, pack or distribute such drug. 46 47 § 54.1-3457. Prohibited acts. **48** A. For the purposes of this chapter, "counterfeit drug" means a substance which, or the container or labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, 49 50 imprint, number, or device, or any likeness thereof, of a manufacturer, distributor, or dispenser other 51 than the person or persons who in fact manufactured, distributed, or dispensed such substance, and which thereby purports or is represented to be a prescription drug as defined in § 54.1-3401, or the 52 53 product of, or to have been distributed by, such other manufacturer, distributor, or dispenser of such 54 prescription drug. 55 *B*. The following acts shall be prohibited: 1. The manufacture, sale, or delivery, holding, or offering for sale of any drug, device, or cosmetic 56 57 that is adulterated or misbranded. 2. The adulteration or misbranding of any drug, device, or cosmetic. 58 59 3. The receipt in commerce of any drug, device, or cosmetic that is adulterated or misbranded, and

3/23/10 19:47

SB1178S1

Ŋ

67

60 the delivery or proffered delivery thereof for pay or otherwise.

61 4. The sale, delivery for sale, holding for sale, or offering for sale of any article in violation of 62 § 54.1-3421. 63

5. The dissemination of any false advertisement.

64 6. The refusal to permit entry or inspection, or to permit the taking of a sample, or to permit access 65 to or copying of any record. 66

7. The giving of a false guaranty or undertaking.

8. The removal or disposal of a detained article in violation of § 54.1-3459.

68 9. The alteration, mutilation, destruction, obliteration, or removal of the whole or any part of the 69 labeling of, or the doing of any other act with respect to a drug, device, or cosmetic, if such act is done 70 while such article is held for sale and results in such article being adulterated or misbranded.

10. The forging, counterfeiting, simulating, or falsely representing, or without proper authority using 71 72 any mark, stamp, tag, label, or other identification device authorized or required by regulations 73 promulgated under the provisions of this chapter or of the federal act.

74 1110. The using by any person to his own advantage, or revealing, other than to the Board or its 75 authorized representative or to the courts when relevant in any judicial proceeding under this chapter of 76 any information acquired under authority of this chapter concerning any method or process which as a 77 trade secret is entitled to protection.

78 4211. The using, on the labeling of any drug or in any advertisement relating to such drug, of any 79 representation or suggestion that an application with respect to such drug is effective under § 54.1-3421, 80 or that such drug complies with the provisions of such section.

1312. In the case of a drug distributed or offered for sale in this the Commonwealth, the failure of 81 the manufacturer, packer, or distributor thereof to maintain for transmittal, or to transmit, to any 82 practitioner licensed by applicable law to administer such drug who makes written request for 83 84 information as to such drug, true and correct copies of all printed matter which is required to be 85 included in any package in which that drug is distributed or sold, or such other printed matter as is 86 approved under the federal act. This subdivision shall not be construed to exempt any person from any 87 labeling requirement imposed by or under other provisions of this chapter.

88 1413. Placing or causing to be placed upon any drug or device or container, with intent to defraud, 89 the trade name or other identifying mark, or imprint of another or any likeness of any of the foregoing; 90 or selling, dispensing, disposing of or causing to be sold, dispensed or disposed of, or concealing or 91 keeping in possession, control or custody, with intent to sell, dispense or dispose of, any drug, device or 92 any container thereof, with knowledge that the trade name or other identifying mark or imprint of 93 another or any likeness of any of the foregoing has been placed thereon in a manner prohibited by this 94 section or making, selling, disposing of, or causing to be made, sold or disposed of, or keeping in 95 possession, control or custody, or concealing any punch, die, plate, stone, or other thing designed to 96 print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or device of 97 another or any likeness of any of the foregoing upon any drug or container or labeling thereof so as to 98 render such drug a counterfeit drug.

99 15. The doing of any act which causes a drug to be a counterfeit drug, or the sale or dispensing, or 100 the holding for sale or dispensing, of a counterfeit drug.

101 14. Manufacturing, selling, distributing, dispensing, facilitating the distribution or dispensing, or 102 holding for distribution or dispensing any counterfeit drug as defined in this section.

1615. Dispensing or causing to be dispensed a different drug or brand of drug in place of the drug or 103 104 brand of drug ordered or prescribed without the permission of the person ordering or prescribing, except as provided in § 54.1-3408.03 relating to dispensing of therapeutically equivalent drugs. 105 106

§ 54.1-3458. Violations; increased penalty.

A. Any person who violates any of the provisions of § 54.1-3457 shall be guilty of a Class 2 107 108 misdemeanor, except that any person who knowingly and willfully violates subdivision B 13 or B 14 of § 54.1-3457 shall be guilty of a Class 5 felony. 109

110 B. No person shall be subject to the penalties of this section for having violated subdivisions B 1 and 111 B 3 of § 54.1-3457 if he establishes a guaranty or undertaking signed by, and containing the name and 112 address of, the person residing in this the Commonwealth from whom he received in good faith the article, to the effect that such article is not adulterated or misbranded within the meaning of this chapter. 113

114 C. No publisher, radio-broadcast licensee, or agency or medium for the dissemination of an advertisement, except the manufacturer, packer, distributor, or seller of the article to which a false 115 116 advertisement relates, shall be liable under this section for the dissemination of such false advertisement, unless he has refused, on the request of the Board, to furnish the Board the name and post-office 117 address of the manufacturer, packer, distributor, seller, or advertising agency, residing in this the 118 119 Commonwealth who caused him to disseminate such advertisement.

120 That the provisions of this act may result in a net increase in periods of imprisonment or 2. commitment. Pursuant to § 30-19.1:4, the estimated amount of the necessary appropriation cannot 121

122 be determined for periods of imprisonment in state adult correctional facilities and is \$0 for 123 periods of commitment to the custody of the Department of Juvenile Justice.